New Malaria Vaccine Shows High Efficacy in African Trials

Oxford University and Serum Institute of India’s new malaria vaccine, R21/Matrix-M™, has shown high efficacy in trials in Africa, with over three-fourths of children in the 5–36 months age group protected from the disease during the first year of follow-up. The vaccine, administered in three doses with a booster after 12 months, maintained good efficacy over the following six to 12 months. This marks the second malaria vaccine to achieve WHO pre-qualification, offering hope in the fight against malaria.